AnGes Obtains Conditional Approval in Japan for HGF Gene

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
43
AnGes Obtains Conditional Approval in Japan for HGF Gene Therapy to Treat Critical Limb Ischemia

TOKYO, April 05, 2019 (GLOBE NEWSWIRE) -- AnGes, Inc., a biopharmaceutical company focused on developing innovative gene-based medicines for treating serious diseases, announced today that they have obtained conditional approval (“Approval with Conditions and Time Limit”) from the Japanese Ministry of Health, Labour and Welfare (MHLW) for HGF plasmid to treat patients with critical limb ischemia (CLI).

HGF plasmid is the first gene therapy product to be approved in Japan, for the improvement of ulcers in patients suffering from chronic arterial occlusion (arteriosclerosis obliterans and Buerger’s disease) who have had an inadequate response to standard pharmacotherapy and who experience difficulty in undergoing revascularization. AnGes applied for marketing approval to the MHLW in January 2018 based on positive results from the randomized, placebo-controlled phase three trial and investigator-led clinical study conducted in Japan. HGF plasmid is one of the first gene therapy products to be approved for a non-genetic disease with chronic and progressive symptoms.

In accord with the conditions of the approval, AnGes will conduct a confirmatory study for all patients who receive treatment with HGF plasmid under the conditional approval and will submit an application to lift the conditions within five years.

AnGes has granted to Mitsubishi Tanabe Pharma Corporation the marketing rights to HGF plasmid in Japan and the U.S.A. for treating peripheral arterial diseases including CLI. Mitsubishi Tanabe is responsible for sales and marketing of the product.

About Critical Limb Ischemia (CLI)
CLI is caused by decreased arterial blood flow in a lower limb due to arteriosclerosis, for which risk factors include diabetes, hypertension and smoking. The disease is estimated to newly affect approximately 500,000 patients every year in the U.S.A. CLI causes severe pain and/or ulcers, often leading to limb amputation when there are no remaining therapeutic options, and consequently quality of life for such patients deteriorates dramatically.

About HGF plasmid
HGF plasmid is a DNA plasmid which encodes human Hepatocyte Growth Factor (HGF) gene, an angiogenic (new blood vessel growth) factor. It is administered intramuscularly into a lower limb and is anticipated to stimulate growth of new blood vessels leading to improved blood flow.

About AnGes
AnGes is a biopharmaceutical company focused on the development and commercialization of gene-based medicines including gene therapy and oligonucleotide molecules. In addition to HGF plasmid, which is the company’s lead product, AnGes is developing NF-kB Decoy oligonucleotide for the treatment of inflammatory diseases. The company has facilities located in Tokyo and Osaka, Japan and is listed on the Mothers Stock Exchange in Tokyo, a market for emerging companies.

About Mitsubishi Tanabe Pharma Corporation
Mitsubishi Tanabe Pharma, which was founded in 1678, has its headquarters in Doshomachi, Osaka, which is the birthplace of Japan’s pharmaceutical industry. With business centered on ethical pharmaceuticals, Mitsubishi Tanabe Pharma is a well-established company and has the longest history of any listed company in Japan. In accordance with the corporate philosophy of “contributing to the healthier lives of people around the world through the creation of pharmaceuticals,” the Company formulated the key concept of Open Up the Future under the Medium-Term Management Plan 16-20. Through the discovery of drugs that address unmet medical needs, centered on its priority disease areas — autoimmune diseases, diabetes and kidney diseases, central nervous system diseases, and vaccines — Mitsubishi Tanabe Pharma will strive to contribute to the health of patients around the world.

Forward-Looking Statement
This news release contains forward-looking statements. Any forward-looking statements are based on the current expectations of the company’s management and are subject to significant risks and uncertainties.

Disclaimer: This is a translation of a news release published in Japanese. In the event of any deviations between the two language versions, the original document in Japanese shall take precedence.

AnGes, Inc. Corporate Communications TEL: +81-3-5730-2641, FAX: +81-3-5730-2635 https://www.anges.co.jp Mitsubishi Tanabe Pharma Media contacts: TEL: +81-6-6205-5119 Investor contacts: TEL: +81 6 6205 5110 https://www.mt-pharma.co.jp/.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Toledo Crosswalk Death Lawsuit Raises Hard Questions

Updated Category News Views 170

A painted crosswalk is supposed to mean something, and that is the grim center of the lawsuit filed over Judy Tanner’s death in Toledo. Tanner, 20, was walking home from work on September 10, 2026, when she was struck and killed while crossing the street. Her estate is now suing, alleging that the 31-year-old driver failed to yield as Tanner legally used the crosswalk....

Continue Reading
Avelo Tests Loyalty Math With WeSalute Fare Discounts

Updated Category News Views 115

Airline discounts can look like generosity until the load factor starts talking back. Avelo Airlines has joined WeSalute with fare discounts for active-duty military members, veterans, first responders, nurses, medical professionals, public servants, teachers and eligible family members. It is a sensible move for a young carrier built around smaller airports and lower...

Continue Reading
Voltage Energy's Microgrid Launches at RE+ 2026

Updated Category News Views 88

Voltage Energy Unveils New Power Systems In the swirling chaos of energy innovation, Voltage Energy is trying to carve its path at the heart of RE+ 2026. Out in Las Vegas, amidst the buzz of renewable energy tech, they introduced their Microgrid System (MGS) along with two new electrical balance of system (EBOS) products—the Load Break Disconnect Box (LBD) and Combiner...

Continue Reading
Exiger's CEO Honored for Military Support Excellence

Updated Category News Views 10

Recognizing Civilian and Military Leadership When you hear "recognition in the military sector," it isn't just a pat on the back. It's a whole parade of brass hats and high-flyers giving their nods. So, November 10th wasn't just any regular day—Brandon Daniels, CEO of Exiger, gets a shiny, prestigious Five-Star Award for his "extraordinary support" of our military...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 23

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Unishippers Climbs 18 Slots on 32.4% Sales Growth Run

Updated Category News Views 122

Thirty new franchise units can move the needle fast Unishippers did not inch its way up the Franchise Times Top 400; it put up a number that deserves a hard look. Sales rose 32.4% in 2025, the company added 30 franchise units, and the result was an 18-place jump to No. 81 on the 2026 ranking. In the shipping category, it was named the sales-growth leader. For a business...

Continue Reading
Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 118

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading
Madrigal Pharmaceuticals Faces Legal Scrutiny Over Data

Updated Category News Views 17

Legal Storm Brews for Madrigal Pharmaceuticals Watch out, here comes another storm for Madrigal Pharmaceuticals, folks. This ain't no small drizzle either; it's a full-on legal monsoon, and it's soaked straight through the walls of their executive suite. We're talking a whistleblower sending alarm bells ringing about data fudging and some dodgy boardroom maneuvers—as if...

Continue Reading
Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 160

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Inhabit Puts AI Across Its Property Management Stack

Updated Category News Views 72

Property managers do not need another shiny chatbot; they need fewer dropped leads, fewer invoice-entry mistakes and less staff time burned chasing routine answers. That is the sensible hook in Inhabit's OPTECH 2026 announcement. The company is spreading AI, integrations and scalability work across ResMan, Anyone Home, ePremium, Nationwide Compliant and several adjacent...

Continue Reading

Top 5 Most Recently Viewed Articles

Bladex Reports Impressive Q1 Earnings with Substantial Growth

Updated Category News Views 256

Bladex Financial Performance in Q1 Banco Latinoamericano de Comercio Exterior, S.A. (NYSE: BLX), commonly referred to as Bladex, has announced strong financial outcomes for the first quarter of the year. The bank recorded a net profit of $51.7 million, equating to $1.40 per share, reflecting a year-over-year increase of 1%. This impressive result has contributed to an...

Continue Reading
Opportunities Open Up at Linnet Corner for Seniors

Updated Category News Views 426

Exciting Housing Opportunities for Seniors The Housing Authority of the City of Alameda (AHA) is thrilled to announce the opening of a housing wait list for its newest community, Linnet Corner. Designed specifically for seniors aged 62 and older, this community will offer modern living options in a prime location. With proper access to public transportation, grocery...

Continue Reading
Vistra Corp's Future: Sustaining Growth and Performance

Updated Category News Views 426

Vistra Corp: A Look Ahead at Potential Growth in 2025 Vistra Energy Corp (NYSE: VST) has gained significant attention among investors due to its impressive performance. The company's stock experienced a remarkable 260% increase in value, cementing its position as the second-best performer in its sector. As we begin 2025, Vistra has already displayed positive momentum with...

Continue Reading
Relive Health's New Coral Gables Center Promotes Wellness

Updated Category News Views 346

Relive Health's New Coral Gables Location Set to Energize Wellness Relive Health is excited to announce the grand opening of its latest wellness center in Coral Gables. This expansion reflects the company's commitment to enhancing the health and vitality of communities through cutting-edge wellness solutions. A Comprehensive Wellness Experience This new clinic offers a...

Continue Reading
EssilorLuxottica and Meta Unveil Next-Gen AI Glasses in 2025

Updated Category News Views 456

Exciting Innovations in Wearable Technology EssilorLuxottica and Meta Platforms, Inc. have unveiled their latest advancements in the realm of AI glasses at the recent Meta Connect event. Building on their successful collaboration, these two industry leaders are set to redefine how consumers interact with technology through innovative wearables. The newest models,...

Continue Reading